hydroxyurea has been researched along with Leukemia, Megakaryoblastic, Acute in 3 studies
Leukemia, Megakaryoblastic, Acute: An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sironi, M | 1 |
| Bertola, G | 1 |
| Lodato, A | 1 |
| Spinelli, M | 1 |
| Sciariada, L | 1 |
| Thiesing, JT | 1 |
| Ohno-Jones, S | 1 |
| Kolibaba, KS | 1 |
| Druker, BJ | 1 |
| Stamatopoulos, K | 1 |
| Yataganas, X | 1 |
| Papadaki, T | 1 |
| Paterakis, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomised Multicentre Phase IV Study to Compare Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec® in Combination With Interferon Alpha at Low Doses in the Treatment of Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukaemia[NCT00390897] | Phase 4 | 360 participants | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for hydroxyurea and Leukemia, Megakaryoblastic, Acute
| Article | Year |
|---|---|
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Humans; Hydroxyurea; Leukemia | 2003 |
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Cell Division; Cell Survival; Cytarabine; Daunorubi | 2000 |
Unusually prolonged survival of a case of acute megakaryoblastic leukemia secondary to long-standing polycythemia vera.
Topics: Bone Marrow; Combined Modality Therapy; Disease Progression; Erythrocyte Transfusion; Female; Humans | 2002 |